Written on: December 31, 2024 by SprayTM
Reckitt Benckiser Group Plc acquired a pharmaceutical site in Wilson, NC, that will expand its U.S. manufacturing footprint and allow it to produce Mucinex products to meet increased consumer demand for cold and flu symptom relief, the company said.
Reckitt invested £155 million ($200 million) in the site to establish a state-of-the-art manufacturing facility, which will help ensure a more resilient supply chain in its largest market. Located in the vicinity of the “Research Triangle” life science hub, the Wilson factory will become Reckitt’s biggest over-the-counter (OTC) manufacturing facility in the U.S. and is expected to create nearly 300 jobs.
“The Wilson facility will greatly increase our Mucinex production capacity, localize more manufacturing, and enable us to better serve our customers and consumers,” said Harald Emberger, Chief Supply Officer, Reckitt.
Added Chris Tedesco, Senior VP, Health for North America, Reckitt: “Demand for Mucinex products has increased over historical pre-pandemic averages, and the factory in Wilson enables us to increase access and meet future demand during in-season and off-season surges.”
Tedesco continued, “We will service demand with greater agility, prepare for long-term growth and deliver new innovations like Mucinex Mighty Chews and Mucinex 2-in-1 Nasal Spray.”
The facility is approximately 310,000 sq ft. In the future, the facility also will have capabilities to support additional products including Move Free and Biofreeze. In addition to creating hundreds of new factory jobs, the facility will also support local jobs in construction, engineering and transportation to help distribute Reckitt products across the country.